Search Results
Your search for ,ITS matches 8694 pages
Showing 8151 - 8200Joseph Smith, Jr, MD, Awarded Huggins Medal
The Society of Urologic Oncology (SUO) recognized Joseph Smith, Jr, MD, William L. Bray Professor of Urologic Surgery at Vanderbilt University School of Medicine, with the Huggins Medal, its highest honor. Dr. Smith was chosen for his lifetime contributions to the progress in treatment for patients ...
Are Academic Cancer Centers a National Treasure?
The Association of American Cancer Institutes (AACI) is developing a marketing campaign to highlight the value of academic cancer centers to their communities and the nation. Called “The Academic Difference,” the 2-year campaign is the initiative of AACI President George J. Weiner, MD, Director of...
ASH Awards Inaugural Giuseppe Bigi Memorial Award in Hematopoiesis and Stem Cells to Marilena Ciciarello, PhD
The American Society of Hematology (ASH) named Marilena Ciciarello, PhD, of the University of Bologna, the inaugural recipient of the ASH Giuseppe Bigi Memorial Award for Achievement in Hematopoiesis and Stem Cells for her research on the role of stem cells in leukemia initiation and progression....
2015 NCI Outstanding Investigator Award Recipients
The first class of National Cancer Institute (NCI) Outstanding Investigator Award recipients showcases the cutting edge of oncologic research and the 43 investigators behind it. NCI’s Outstanding Investigator Award supports accomplished leaders in cancer research, who are providing significant...
A Primary Care Doctor’s Tough-Love Medicare Fix
Bookmark Title: Curing Medicare: One Doctor’s View of How Our Health Care System Is Failing the Elderly and How to Fix It Author: Andy Lazris, MD Publisher: CreateSpace Publication date: September 13, 2014 Price: $13.75; paperback, 290 pages Several years ago I decided to write a book about...
Opening Doors: ASCO Aims to Increase Workforce Diversity Through Physician Mentoring Program
Olumide Gbolahan, MD, faced a familiar dilemma among aspiring oncologists. Dr. Gbolahan, an internal medicine resident of the Morehouse School of Medicine, wanted extra time and experience in an oncologic elective summer rotation to ease his transition from internal medicine to oncology. Unsure of...
ASCO Guides Members Through MACRA Implementation With a Robust Set of New Resources
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), passed earlier this year, repealed the fundamentally flawed Sustainable Growth Rate formula and introduced significant changes in how Medicare will pay oncologists for the care they provide in the coming years. The new law will be...
The Promise of Immune Checkpoint Blockade in Cancer Therapy
The concept of using activation of the innate immune system and an inflammatory response against a bacterial component to instigate an antitumor response was studied in the 1960s, which led to the development of intravesical bacillus Calmette-Guérin, now used in the treatment of superficial bladder ...
Necitumumab in Metastatic Squamous Non–Small Cell Lung Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 24, 2015, necitumumab (Portrazza) was approved for use ...
Ductal Carcinoma in Situ and Relevant Endpoints for Omission of Standard Treatments: Are We There Yet?
The optimal management strategy for ductal carcinoma in situ has become increasingly controversial with respect to potential overdiagnosis and overtreatment. Much of the controversy for ductal carcinoma in situ stems from its exceptional breast cancer–specific survival, which approaches close to...
Journal of Oncology Practice Expands Research Coverage and Debuts a New Look
Launched by ASCO in 2005 to provide oncologists with original research on the delivery of high-quality cancer care, the Journal of Oncology Practice (JOP) enters its 11th year with a new look and feel. Beginning in January 2016, JOP will be copublished by ASCO and Harborside Press, the publisher of ...
Clinical Trial System Badly in Need of Overhaul, Say Panelists at Friends-Brookings Conference
Cancer clinical trials in three distinct phases, as they have been conducted for decades, are probably no longer the best way to bring a drug or biologic agent to market. This was the consensus of three panels at the 8th Annual Conference on Clinical Cancer Research convened by Friends of Cancer...
St. Jude Names Carlos Rodriguez-Galindo, MD, Director of International Outreach Program
Carlos Rodriguez-Galindo, MD, an international leader in pediatric solid tumor research, is joining St. Jude Children’s Research Hospital to head the International Outreach Program. Dr. Rodriguez-Galindo will serve as International Outreach Program Director and an executive vice president. He will...
Optimizing the Treatment of HIV-Associated Lymphoma
Non-Hodgkin lymphoma (NHL) associated with human immunodeficiency virus (HIV) infection generally can be treated the same as lymphoma in non–HIV-infected patients, with a few caveats, according to Lawrence D. Kaplan, MD, of the Helen Diller Family Comprehensive Cancer Center of the University of...
Nivolumab as Single-Agent Treatment for BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 24, 2015, nivolumab (Opdivo) was approved for use as...
Promising Upfront Combination in Older Patients With Acute Lymphoblastic Leukemia
Frontline treatment with the antibody-drug conjugate inotuzumab ozogamicin plus deintensified chemotherapy is a promising option for older patients with Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). Phase II results suggest that this combination has the ability to improve...
Nivolumab in Advanced Renal Cell Carcinoma After Antiangiogenic Therapy
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 23, 2015, nivolumab (Opdivo) was approved for use in...
Expert Point of View: Mark J. Levis, MD
Putting this trial into context, Mark J. Levis, MD, of the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, said: “Six different FLT3 inhibitors have advanced into phase III trials. Midostaurin in the only one that has made it to the ‘station.’” “The fact that midostaurin is...
A Shot to End Cancer: HPV Vaccination
As health-care providers, we have an obligation and a responsibility not only to care for our patients, but also to educate them—and the general public—about their cancer risk and ways to reduce or prevent it. We are living in the golden era of cancer prevention and treatment, made possible by...
DNA Repair Enzyme Identified as a Potential Brain Cancer Drug Target
Rapidly dividing cells rely on an enzyme called Dicer to help them repair the DNA damage that occurs as they make mistakes in copying their genetic material over and over for new cells. Researchers have built on the discovery of Dicer’s role in fixing DNA damage to uncover a new potential...
ESMO Asia 2015: Results From the KEYNOTE-010 Trial Show Pembrolizumab Benefit in Patients With NSCLC
More patients with advanced non–small cell lung cancer (NSCLC) could benefit from pembrolizumab (Keytruda), said Roy Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven. Dr. Herbst presented promising results from the pivotal phase...
FDA Expands Pembrolizumab Label to Include Approval in Initial Treatment of Unresectable or Metastatic Melanoma
On December 18, 2015, the U.S. Food and Drug Administration (FDA) expanded the pembrolizumab (Keytruda) label to include approval of the drug for the treatment of patients with unresectable or metastatic melanoma. This expansion now includes the initial treatment of patients with unresectable or...
Mental Health Status Prior to Radical Cystectomy Can Indicate Risk of Complications
A patient's mental health prior to surgery can influence postoperative outcomes. Removal of the bladder, or radical cystectomy, is an effective treatment for locally advanced bladder cancer, but complications occur in as many as 66% of patients. In a study published by Sharma et al in The Journal...
Bruce E. Johnson, MD, FASCO, Elected ASCO President for 2017–2018 Term
Bruce E. Johnson, MD, FASCO, has been elected President of ASCO for the term beginning in June 2017. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2016. Additionally, four new members were elected to the ASCO Board of Directors, as well as three new...
New ‘Condensed’ Grading System Shown to Be Accurate for Predicting Prostate Cancer Outcomes
Using information gleaned from more than 20,000 men, researchers at Johns Hopkins have affirmed the value of their alternative system for assessing the likelihood of growth and spread of prostate cancer. The new grading system, they said, is not only easier to use and understand, but also more...
Preoperative Use of Blood-Thinning Drugs Is Safe for Patients With Cancer
Among patients undergoing major cancer operations, the preoperative use of blood-thinning drugs such as heparin does not increase rates of major bleeding or transfusions, and is associated with a decreased risk of blood clots, according to new study results published by Selby et al in the Journal...
HDAC Inhibitors May Help Prevent Cisplatin-Based Kidney Damage
A class of drugs used increasingly to help fight cancer may have the additional benefit of protecting the kidneys when packaged with the powerful chemotherapy agent cisplatin. These findings were published by Ranganathan et al in Kidney International. The nearly 40-year-old cisplatin can be a...
Colorectal Cancer Risk Varies Based on Latino Subgroup Affiliation
In the first study of its kind, University of Southern California (USC) researchers have found that colorectal cancer risk in Californian Latinos varies widely depending on the country of origin. Their study was published by Stern et al in Cancer Causes & Control. “Hispanics are a very...
FDA Approves Uridine Triacetate for Emergency Treatment of Fluorouracil or Capecitabine Overdose
The U.S. Food and Drug Administration (FDA) today approved uridine triacetate (Vistogard) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil (5-FU) or capecitabine, or who develop certain severe or life-threatening toxicities within...
SABCS 2015: Phase III BELLE-2 Trial Meets Primary Endpoint of Progression-Free Survival
Among women with locally advanced or metastatic hormone receptor–positive breast cancer that was resistant to hormone therapy, those who had mutated PIK3CA detected in their blood benefited from a combination of the investigational PI3K inhibitor buparlisib and fulvestrant (Faslodex),...
ASH 2015: Children With Acute Lymphoblastic Leukemia Benefit From Prophylactic Antibiotics During Induction Chemotherapy
Prophylactic antibiotics significantly reduce the risk of serious bacterial infections in children during the critical first month of treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer, according to a study led by investigators from Dana-Farber/Boston Children's...
ASH 2015: Midostaurin Improves Survival in Patients With FLT3-Mutated Acute Myeloid Leukemia Aged 18–60
A study presented by Stone et al at the 57th American Society of Hematology (ASH) Annual Meeting described a phase III trial of the first targeted therapy for genetically defined subset of patients with acute myeloid leukemia and its improvement of their survival (Abstract 6). Acute myeloid...
Systematic Review Informing ACS Updated Guideline for Breast Cancer Screening in Women at Average Risk
Findings of a systematic review of the benefits and harms of breast cancer screening commissioned by the American Cancer Society (ACS) to inform its updated guideline on screening in average-risk women were reported in JAMA by Myers et al of the Duke Evidence Synthesis Group. Their findings were...
ASH 2015: American Society of Hematology Releases Compilation of Top Choosing Wisely Recommendations Relevant to Hematology
The American Society of Hematology (ASH) has released a list of five hematology-related tests and procedures to question based on recommendations from other medical societies taking part in the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign. This list...
FDA Approves Necitumumab Combination for Metastatic Squamous NSCLC
The U.S. Food and Drug Administration today approved necitumumab (Portrazza) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of nonsquamous NSCLC....
FDA Approves Nivolumab to Treat Advanced Kidney Cancer
The U.S. Food and Drug Administration today approved nivolumab (Opdivo) to treat patients with metastatic renal cell carcinoma who have received a prior antiangiogenic therapy. Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2,...
Chitosane-Based Injectable Biogel Delivers Anticancer Agents Directly Into Tumors in Laboratory Setting
A new, injectable “biogel” is effective in delivering anticancer agents directly into cancerous tumors and killing them, according to a study published by Monette et al in Biomaterials. The technology was developed by researchers at the University of Montreal Hospital Research Centre...
Study Advances Potential Test to Distinguish Precancerous Pancreatic Cysts From Harmless Ones
In a retrospective analysis of data from 130 patients with pancreatic cysts, scientists at Johns Hopkins have used gene-based tests and a fixed set of clinical criteria to more accurately distinguish precancerous cysts from those less likely to do harm. The findings may eventually help some...
Patients With Breast Cancer Who Have Prescription Drug Benefits, Higher Incomes More Likely to Start and Continue Hormonal Therapy
A University of Colorado Cancer Center study published by Bradley et al in Breast Cancer Research and Treatment showed that patients with breast cancer whose health insurance plans included prescription drug benefits were 10% more likely to start important hormonal therapy than patients who did not ...
Yoga Helps Maintain Quality of Life, May Lessen Side Effects in Men Undergoing Prostate Cancer Treatment
Men with prostate cancer who are undergoing radiation therapy can benefit from yoga, researchers at the Perelman School of Medicine at the University of Pennsylvania reported at the Society for Integrative Oncology’s 12th International Conference. The new, first-of-its-kind study, led...
Kidney Failure and Its Treatment May Impact Cancer Risk
For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published by Yanik et al in the Journal of the American Society of Nephrology, suggest the need for persistent cancer...
New Prediction Model May Provide More Accurate Assessment of Breast Cancer Risk in Hispanic Women
A prediction model created for projecting absolute invasive breast cancer risk in Hispanic women provides a more accurate assessment of their risk of developing breast cancer compared with existing models that are based on data from non-Hispanic women, according to a new study by Banegas et al....
Investigational NAE Inhibitor Pevonedistat Shows Potential Activity in Patients With Relapsed/Refractory Lymphoma
A phase I study evaluating the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma has found...
Experimental Drug Shown to Prevent Neuroblastoma in Preclinical Study
Australian scientists have identified a critical molecular “feedback loop” that helps initiate and drive neuroblastoma, a cancer of the nervous system in children that is triggered in embryonal nerve cells. This feedback loop massively accelerates cancer development. The research team...
Increasing Use of Preoperative Breast MRI Linked to Increased Postdiagnostic Imaging and Biopsy, Mastectomy, and Surgery Delay
In a Canadian population-based study reported in JAMA Oncology, Arnaout et al found that breast magnetic resonance imaging (MRI) is increasingly used in preoperative evaluation of women with breast cancer and that its use is associated with increased likelihood of confirmatory breast imaging,...
ABC3: Patients Speak Out Against 'Damaging Messages' About Metastatic Breast Cancer, Call for Inclusion in Discussion About Treatment Costs
Organizations that issue “damaging messages” about advanced breast cancer need to be identified and educated to change the way they talk about the disease, a patient told the Advanced Breast Cancer Third International Consensus Conference in Lisbon, Portugal, on November 5, 2015. In...
Study Shows Wide Variation in Costs to Treat Low-Risk Prostate Cancer
University of California, Los Angeles (UCLA) researchers have described costs across the entire care process for low-risk prostate cancer—from the time a patient checks in for his first appointment to his post-treatment follow-up testing—using time-driven activity-based costing. For the ...
Only 1 in 5 U.S. Patients With Pancreatic Cancer Gets Key Blood Test at Diagnosis
Only 1 in 5 patients with pancreatic cancer in the United States receives a widely available, inexpensive blood test at diagnosis that can help predict relative outcome (compared to others with the same disease stage) and guide treatment accordingly, a Mayo Clinic study showed. People who test...
Stool DNA Test Accurate in Screening for Colorectal Cancer in Alaska Native People
Cologuard stool DNA testing for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of the world's highest rates of colorectal cancer, concluded researchers from the Alaska Native Tribal Health Consortium and Mayo Clinic. The...
Study Identifies Splicing Alterations That Enable Resistance to CD19 CAR T-Cell Immunotherapy
Although the CD19 antigen expressed on most B-cell acute lymphoblastic leukemias (ALL) can be targeted with chimeric antigen receptor–armed T cells (CART-19), relapse rates among pediatric and adult patients with the cancer remain high. In this study by Sotillo et al, the researchers...
